F. No. ND/MA/24/000119
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
New Drugs Division

FDA Bhawan, Kotla Road,
New Delhi-110002

To
M/s Precise Biopharma Pvt. Ltd.,
E-311, E-312, Eastern Business District
LBS Road, Bhandup (W), Mumbai,
Maharashtra (India) – 400078.

Subject: A Phase III, Randomized, Open Label, Active Controlled, Prospective, Parallel Group, Comparative, Multicentric Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Abaloparatide Injection in Comparison with Teriparatide Injection for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture" vide protocol no. CT/2024/41, version no. 00, dated 22-JUL-2024 – regarding.

Ref: Your application no. ND/CT21/BO/2024/44829 dated 13.08.2024

Sir,

With reference to your application, please find enclosed herewith the permission in **Form CT-06 vide no. CT/ND/16/2025** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully

RAJEEV SINGH RAGHUVANSHI
Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2025.08.06 17:45:03 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

Condition of permission

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;

(ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics

Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;

(ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;

(xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance

with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.

(xix) The informed Consent Document including ICF and Patient Information Sheet should clearly mention in understandable language about the details of the drug therapy that the patient may or may not receive.

(xx) It may kindly be noted that merely granting permission to conduct Clinical Trial study with drug doesn't convey or imply that based Clinical Trial data generated with the drug, permission to market this drug will automatically be granted to you.

(xxi) **Firm shall provide post-trial access of study drugs to subjects for period of one year after completion of clinical trial.**

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR ~~INVESTIGATIONAL NEW DRUG~~

Permission No. CT/ND/16/2025

The Central Licensing Authority hereby permits **M/s Precise Biopharma Pvt. Ltd., E-311, E-312, Eastern Business District, LBS Road, Bhandup (W), Mumbai, Maharashtra (India) – 400078, Telephone No.: 02267828600 FAX: 2221028955 E-Mail: corporate@precisebiopharma.com** to conduct Phase III clinical trial of the new drug as per Protocol No. CT/2024/41, version no. 00, dated 22-JUL-2024 in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:-

Names of the new drug or investigational new drug:	**Abaloparatide Injection 3120 mcg/1.56 mL**
Therapeutic class:	Parathyroid Hormone related protein PTHrP analogue
Dosage form:	Solution for Injection
Composition:	Each prefilled cartridge contains: Abaloparatide: 3120 mcg Excipients: q.s. Water for Injection: q.s. to 1.56
Indication:	Abaloparatide is Indicated for treatment of post-menopausal women with osteoporosis at high risk of fracture

Details of clinical trial sites-

Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
1	**Dr. Neerav Anand Singh (Orthopaedics)** Gangasheel Advanced Medical Research Institute, C17, Deen Dayal Puram, Rajendra Nagar, Bareilly-243122, Uttar Pradesh	Institutional Ethics Committee, Gangasheel Advanced Medical Research Institute, Director Office, Ground Floor, C17, Deen Dayal Puram, Bareilly-243001, Uttar Pradesh ECR/1319/Inst/UP/2019/RR- 24
2	**Dr. Sachin Yadav (Orthopaedics)** Department of Ortho, Swarooprani Motilal Nehru Medical College, Prayagraj-211001, Uttar Pradesh	Institutional Ethics Committee, Motilal Nehru Medical College, George Town, Prayagraj, Allahabad-211002, Uttar Pradesh. ECR/922/Inst/UP/2017/RR-22
3	**Dr. Azad Khan (Orthopaedics)** Department of Orthopaedic, Subharti Medical College and Hospital, Subharti Puram, NH-58, Delhi-Haridwar Bypass Road, Meerut-250005, Uttar Pradesh	Institutional Ethics Committee, Subharti Medical College and Hospital, Subhartipuram, NH 58, Delhi-Haridwar Bypass Road, Meerut- 250005, Uttar Pradesh. ECR/256/Inst/UP/2013/RR-24

4	**Dr. Rakesh Verma (Orthopaedics)** Jawahar Lal Nehru (J.L.N) Medical College, Kala Bagh, Ajmer-305001, Rajasthan	Institutional Ethics Committee, Jawahar Lal Nehru Medical College, Kala Bagh, Ajmer-305001, Rajasthan. ECR/1156/Inst/RJ/2018/RR-22
5	**Dr. Kaushik Banerjee (Orthopaedics)** Medical College and Hospital, 88 College Street, Kolkata-700073, West Bengal.	Institutional Ethics Committee for Human Research, Medical College and Hospital, Kolkata, 88, College Street, Kolkata-700073, West Bengal. ECR/287/Inst/WB/2013/RR-24
6	**Dr. Kiran Kumar Mukhopadhyay (Orthopaedics)** Department of Orthopaedic Surgery, Nil Ratan Sarkar Medical College and Hospital, 138, Acharya Jagadish Chandra Bose Road, Kolkata-700014, West Bengal	Ethics Committee, Nil Ratan Sarkar Medical College and Hospital, 138, Acharya Jagadish Chandra Bose Road, Sealdah, Raja Bazar, Kolkata-700014, West Bengal. ECR/609/Inst/WB/2014/RR-20
7	**Dr. Saurabh Khare (Orthopaedics)** SMC Heart Institute and IVF Research Centre, Infront of BSNL Office, Vidhan Sabha Road, Khamardih, Raipur-492007, Chhattisgarh.	SMC Heart Institute Institutional Ethics Committee, SMC Heart Institute and IVF Research Centre, Infront of BSNL Office, Vidhan Sabha Road, Khamardih, Raipur-492007, Chhattisgarh. ECR/1522/Inst/CG/2021
8	**Dr. Patro Bishnu Prasad (Orthopaedics)** All India Institute of Medical Sciences,Bhubaneswar, Odisha.	Institutional Ethics Committee All India Institute of Medical Sciences, Bhubaneswar, Odisha ECR/534/Inst/OD/2014/RR-20
9	**Dr. Rajesh Rana (Orthopaedics)** Srirama Chandra Bhanja Medical College and Hospital, Cuttack, Orissa	Institutional Ethics Committeee Srirama Chandra Bhanja Medical College and Hospital, Cuttack, Orissa ECR/84/Inst/OR/2013/RR-20
10	**Dr. Prateek Lodha (Orthopaedics)** Aatman Hospital, 5, Anveshan Row House, Opp. Umiya Mata Mandir, Bopal-Ghuma Main Road, Bopal Ghuma, Ahmedabad-380058, Gujarat.	Institutional Ethics Committee, Aatman Hospital, 5, Anveshan Row House, Opp. Umiya Mata Mandir, Bopal-Ghuma Main Road, Bopal, Ahmedabad-380058, Gujarat. ECR/1565/Inst/GJ/2021
11	**Dr. Dattaraj Kalidas Nasnolkar (Orthopaedics)** Redkar Hospital and Research Centre, Mumbai-Goa Highway, Oxelbag, Dhargal, Tal-Pernem, Goa-403513.	Redkar Hospital Institutional Ethics Committee (RHIEC), Redkar Hospital and Research Centre, Mumbai-Goa Highway, Oxelbag, Dhargal, Pernem, North Goa-403513. ECR/902/Inst/GA/2018/RR- 21
12	**Dr. Dhadiwal Rajesh Kantilal (Orthopaedics)** Swastik Dhadiwal Hospital, Trambak Road, Opp. Thakkar Bazzar, Matoshree Nagar, Nashik-422002, Maharashtra.	Shree Institutional Ethics Committee Dhadiwal Hospital In Coalition with Shreeji Health Care, Opp. New CBS Trimbak Road, Nashik-422002, Maharashtra ECR/1149/Inst/MH/2018/RR-21

13	**Dr. Rupraj Madhukar Pawar (Orthopaedics)** Supe Heart & Diabetes Hospital and Research Centre, Opp. Adhar Ashram, Near Rungtha School, Gharpure Ghat Road, Nashik-422002, Maharashtra.	Supe Hospital Ethics Committee, Supe Heart Diabetes Hospital and Research Centre, Opp. Adhar Ashram, Gharpure Ghat Near Rungtha School, Ashok Stambha, Nashik-422002, Maharashtra. ECR/272/Inst/MH/2013/RR-24
14	**Dr. Varun A. Bafna (Orthopaedics)** Department of Medicine, Rajarshee Chhatrapati Shahu Maharaj Govt. Medical College and Chhatrapati Pramila Raje General Hospital, Dasara Chowk, Town Hall, Bhausingji Road, Kolhapur-416012, Maharashtra.	Rajarshee Chhatrapati Shahu Maharaj Govt. Medical College Institutional Ethics Committee 2 (RCSMGMCIEC2), Rajarshee Chhatrapati Shahu Maharaj Govt. Medical College and Chhatrapati Pramila Raje General Hospital, Building No. 2, Quarter No. 3, Room No. 7, Dasara Chowk, Town Hall, Bhausingji Road, Kolhapur-416007. ECR/703/Inst/MH/2015/RR-20
15	**Dr. B. Gowtham (Orthopaedics)** Great Eastern Medical School and Hospital, Ragolu, Srikakulam-532484, Andhra Pradesh	Institutional Ethics Committee, Great Eastern Medical School and Hospital, D. No.: 3-351, Ragolu, Srikakulam-532484, Andhra Pradesh. ECR/1521/Inst/AP/2021
16	**Dr. Ladi Lokanadha Rao (Orthopaedics)** Department of Orthopaedics, King George Hospital, Andhra Medical College, Maharanipeta, Visakhapatnam - 530002, Andhra Pradesh.	Institutional Ethics Committee, King George Hospital, Maharanipeta, Collector Office Junction, Visakhapatnam-530002, Andhra Pradesh. ECR/197/Inst/KGH/2013/RR-20
17	**Dr. Bhanoth Valya (Orthopaedics)** In Patient Block, Ground Floor, Department of Orthopaedics, Gandhi Hospital, Musheerabad, Secunderabad - 500003, Telangana.	Institutional Ethics Committee, Gandhi Medical College and Hospital, Musheerabad, Secunderabad-500003, Telangana. ECR/180/Inst/AP/2013/RR-24
18	**Dr. Vikalp Vashishitha (Orthopaedics)** Maharaja Agarsen Superspeciality Hospital, Central Spine, Agrasen Aspatal Marg, Sector 7, Vidhyadhar Nagar, Jaipur-302039, Rajasthan	Institutional Ethics Committee, Maharaja Agarsen Superspeciality Hospital, Central Spine, Agrasen Aspatal Marg, Sector 7, Vidhyadhar Nagar, Jaipur-302039, Rajasthan ECR/1222/Inst/RJ/2019/RR-22

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

RAJEEV SINGH RAGHUVANSHI

Digitally signed by RAJEEV SINGH RAGHUVANSHI
Date: 2025.08.06 17:45:27 +05'30'

(Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

New Delhi